Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03039686
Recruitment Status : Active, not recruiting
First Posted : February 1, 2017
Last Update Posted : February 5, 2020
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).

Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Drug: RO7239361 Drug: Placebo for RO7239361 Phase 2 Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 166 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
Actual Study Start Date : July 6, 2017
Estimated Primary Completion Date : December 30, 2020
Estimated Study Completion Date : December 17, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: RO7239361, dose 1
Take RO7239361 subcutaneously on specified days over a 48 week blinded period
 Drug: RO7239361
Take RO7239361 subcutaneously on specified days over a 48 week blinded period
Experimental: RO7239361, dose 2
Take RO7239361 subcutaneously on specified days over a 48 week blinded period
 Drug: RO7239361
Take RO7239361 subcutaneously on specified days over a 48 week blinded period
Placebo Comparator: Placebo
Placebo solution taken subcutaneously on specified days over a 48 week blinded period
 Drug: Placebo for RO7239361
Take placebo subcutaneously on specified days over a 48 week blinded period


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change from baseline in the North Star Ambulatory Assessment (NSAA) total score in RO7239361 treated participants. [ Time Frame: 48 Week ]
  2. Change from baseline in the in the North Star Ambulatory Assessment (NSAA) total score in placebo treated participants. [ Time Frame: 48 Week ]

Secondary Outcome Measures :
  1. Change from baseline at Week 48 in RO7239361 treated participants compared to placebo treated participants in the 4 Stair Climb Velocity (4SCV) Assessment [ Time Frame: 48 weeks ]
  2. Change from baseline at Week 48 in RO7239361 treated participants compared to placebo treated participants in Stand from supine velocity [ Time Frame: 48 weeks ]
  3. Change from baseline at Week 48 in RO7239361 treated participants compared to placebo treated participants in 10 M walk/run velocity [ Time Frame: 48 weeks ]
  4. Change from baseline at Week 48 in RO7239361 treated participants compared to placebo treated participants in PODCI transfers and basic mobility subscale [ Time Frame: 48 weeks ]
  5. Change from baseline at Week 48 in RO7239361 treated participants compared to placebo treated participants in Proximal lower extremity flexor (knee extension and knee flexion) strength, measured using manual myometry [ Time Frame: 48 weeks ]
  6. Change from baseline at Week 48 in RO7239361 treated participants compared to placebo treated participants in 6 Minute Walk Distance (6MWD) [ Time Frame: 48 weeks ]
  7. Change from baseline at Week 48 in RO7239361 treated participants compared to placebo treated participants in Clinical Global Impression of Change (CGI-C) rating. [ Time Frame: 48 weeks ]
  8. Change from baseline at Week 48 in RO7239361 treated participants compared to placebo treated participants in 95th percentile stride velocity [ Time Frame: 48 weeks ]
    As recorded with the ActiMyo device in a subset of the overall study population.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 11 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with DMD by confirmed medical history and genetic testing
  • Able to walk without assistance
  • Minimum North Star Ambulatory Assessment score of 15 at screening
  • Able to walk up 4 stairs in 8 seconds or less
  • Weigh at least 15 kg (33 lbs)
  • Taking corticosteroids for DMD

Exclusion Criteria:

  • Any behavior or mental issue that will affect the ability to complete the required study procedures
  • Previously or currently taking medications like androgens or human growth hormone
  • Use of a ventilator during the day
  • Unable to have blood samples collected or receive an injection under the skin
  • Concomitant or previous participation at any time in a gene therapy study

Other protocol defined Inclusion/Exclusion Criteria could apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03039686


Locations
Hide Hide 47 study locations
Layout table for location information
United States, Arizona
Neuromuscular Research Center
Phoenix, Arizona, United States, 85028
United States, California
David Geffen School of Medicine at UCLA; Clinical Trials Contract Unit
Los Angeles, California, United States, 90095
Stanford University
Palo Alto, California, United States, 94304
University of California Davis Medical Center
Sacramento, California, United States, 95817
United States, Connecticut
Yale University School of Medicine ; Pulmonary & Critical Care
New Haven, Connecticut, United States, 06510
United States, Florida
University of Florida
Gainesville, Florida, United States, 32607
Nemours Children's Hospital
Orlando, Florida, United States, 32827
United States, Georgia
Rare Disease Research, LLC
Atlanta, Georgia, United States, 30318
United States, Illinois
Rush University Medical Center - PPDS
Chicago, Illinois, United States, 60612
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, Maryland
Kennedy Krieger Institute
Baltimore, Maryland, United States, 21205
United States, Massachusetts
University of Massachusetts Memorial Childrens Medical Center; Department of Neurology
Worcester, Massachusetts, United States, 01655
United States, Missouri
Saint Louis Children's Hospital
Saint Louis, Missouri, United States, 63110
United States, Nevada
Las Vegas Clinic
Las Vegas, Nevada, United States, 89145
United States, Ohio
Cincinnati Childrens Hospital Medical Center;Investigational Pharmacy
Cincinnati, Ohio, United States, 45229
Nationwide Childrens Hospital; Research Institute at Nationwide Childrens Hospital
Columbus, Ohio, United States, 43205
United States, Pennsylvania
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Argentina
Instituto centenario
Buenos Aires, Argentina, C1204AAD
Australia, New South Wales
Children's Hospital Westmead; Paediatrics & Child Health
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Lady Cilento Children's Hospital; Neurosciences Department
South Brisbane, Queensland, Australia, 4101
Australia, Victoria
Royal Children's Hospital
Parkville, Victoria, Australia, 3052
Belgium
UZ Gent
Gent, Belgium, 9000
UZ Leuven; Neurology
Leuven, Belgium, 3000
Canada, Ontario
London Health Sciences Centre; Children's Hospital; Pediatrics
London, Ontario, Canada, N6A 5W9
Children'S Hospital of Eastern Ontario
Ottawa, Ontario, Canada, K1H 8L1
France
Hospices Civils de Lyon
Lyon, France, 69004
Hotel Dieu; Service Pharmacie Essais Cliniques
Nantes, France, 44093
Hopital Armand Trousseau; centre reference Maladies Neuro-musculaires Est parisien Neuropediatrie
Paris Cedex 12, France, 75571
Hopitaux Universitaires de Strasbourg
Strasbourg, France, 67091
Germany
Universitatsklinikum Essen; Innere Klinik
Essen, Germany, 45122
Italy
Fondazione Serena Onlus - CENTRO CLINICO NEMO
Milano, Emilia-Romagna, Italy, 20162
Fondazione Policlinico Universitario A Gemelli; Servizio di Farmacia
Rome, Lazio, Italy, 00168
Az. Osp. Universitaria Pol. G. Martino; Dip. Neuroscienze, Scienze Psichiatriche e Anest.
Messina, Sicilia, Italy, 98125
Japan
Hyogo College of Medicine Hospital
Hyogo, Japan, 663-8501
Miyagi Children's Hospital
Miyagi, Japan, 989-3126
Shinshu University Hospital
Nagano, Japan, 390-8621
National Hospital Organization Osaka Toneyama Medical Center
Osaka, Japan, 560-8552
National Center of Neurology and Psychiatry
Tokyo, Japan, 187-8551
Netherlands
Leids Universitair Medisch Centrum
Leiden, Netherlands, 2333 ZA
Radboud University Nijmegen Medical Centre; Ophthalmology
Nijmegen, Netherlands, 6525 EX
Spain
Hospital Sant Joan De Deu
Esplugues De Llobregas, Barcelona, Spain, 08950
Hospital Universitari i Politecnic La Fe de Valencia; Servicio de Farmacia
Valencia, Spain, 46026
Sweden
Drottning Silvias Barn- och ungdomssjukhus; Kliniken for barnmedicin
Goeteborg, Sweden, 41685
United Kingdom
Alder Hey Children s Hospital; Department of Pediatrics
Liverpool, United Kingdom, L12 2AP
UCL Institute of Child Health & Great Ormond Street Hospital for Children
London, United Kingdom, WC1N 1EH
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
FDA Safety Alerts and Recalls  This link exits the ClinicalTrials.gov site Provides information about the Roche clinical trial NCT03039686 and molecule being investigated in Duchenne  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03039686    
Other Study ID Numbers: CN001-016
2016-001654-18 ( EudraCT Number )
WN40227 ( Other Identifier: Hoffman-La Roche )
First Posted: February 1, 2017    Key Record Dates
Last Update Posted: February 5, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hoffmann-La Roche:
muscular dystrophy
Duchenne's Muscular Dystrophy
DMD
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
 Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked